1083326-75-3

Basic information

• Product Name: N-[2-METHOXY-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-PYRIDINYL]-METHANESULFONAMIDE
• Synonyms: N-[2-METHOXY-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-PYRIDINYL]-METHANESULFONAMIDE;N-(2-Methoxy-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)MethanesulfonaMide;N-[2-(Methyloxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-pyridinyl]methanesulfonamide;6-Methoxy-5-(methylsulfonamido)pyridine-3-boronic acid pinacol ester
• CAS NO: 1083326-75-3
• Molecular Formula: C₁₃H₂₁BN₂O₅S
• Molecular Weight: 328.19224
• EINECS: -0
• Mol File: 1083326-75-3.mol
• Article Data: 25

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: N-[2-METHOXY-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-PYRIDINYL]-METHANESULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2-METHOXY-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-PYRIDINYL]-METHANESULFONAMIDE(1083326-75-3)
• EPA Substance Registry System: N-[2-METHOXY-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-PYRIDINYL]-METHANESULFONAMIDE(1083326-75-3)

Safety Data

• Hazardous Substances Data: 1083326-75-3(Hazardous Substances Data)

Usage

General Description

N-[2-Methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-pyridinyl]-methanesulfonamide, also known as MLN2480, is a chemical compound that belongs to the class of methanesulfonamides. It is a potent and selective inhibitor of protein deacetylase enzyme and has shown promising therapeutic potential in the treatment of cancer. N-[2-METHOXY-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-PYRIDINYL]-METHANESULFONAMIDE works by targeting the activity of the protein deacetylase enzyme, which plays a crucial role in the regulation of gene expression and cellular processes. MLN2480 has been studied extensively in preclinical research and has demonstrated antitumor activity in various cancer types, making it a potential candidate for the development of novel cancer therapies. Additionally, its unique chemical structure and mechanism of action make it a valuable tool for further research in the field of epigenetics and cancer biology.

Upstream product

• 893440-50-1 2-(methyloxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-pyridinamine 
• 124-63-0 methanesulfonyl chloride 
• 884495-39-0 5-bromo-2-(methyloxy)-3-pyridinamine 
• 73183-34-3 bis(pinacol)diborane 
• 1361970-57-1 5-bromo-2-methoxypyridin-3-amine hydrochloride 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 152684-30-5 5-bromo-2-methoxy-3-nitropyridine 
• 1083327-58-5 N-[5-bromo-2-(methyloxy)-3-pyridinyl]methanesulfonamide 

Downstream Products

• 1361970-34-4 N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide tosylate salt 
• 1361970-37-7 N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide mesitylenesulfonate salt 
• 1361970-55-9 N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1-(phenylsulfonyl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide 

Relevant articles and documents

Cnoline compound PI3K kinase inhibitor as well as preparation method and application thereof in pharmacy

The invention provides a cinnoline compound PI3K kinase inhibitor as shown in a formula I. In the cinnoline compound PI3K kinase inhibitor, and R1, R2 and R3 are defined in the specification. The invention also provides a pharmaceutical composition of the

Design, synthesis, and biological evaluation of some novel 4-aminoquinazolines as Pan-PI3K inhibitors

A series of 4-aminoquinazolines derivatives containing hydrophilic group were designed and identified as potent Pan-PI3K inhibitors in this study. The results of antiproliferative assays in vitro showed that this series of compounds had strong inhibition of tumor growth, especially compound 7b for MCF-7 cells but weak inhibition to normal cells. PI3K kinase assay showed that 7b had high activity for three PI3K isoforms with the IC50 values of picomole. The western blot assay indicated that 7b could decrease the phospho-Akt (S473) in a dose-dependent manner. Further experiments showed that 7b could induce apoptosis in MCF-7 cells. Four key hydrogen bonding interactions were found in the docking of 7b with PI3K kinase. All these results suggested that 7b is a potent PI3K inhibitor and could be considered as a potential candidate for the development of anticancer agents.

Development of Flexible and Scalable Routes to Two Phosphatidinylinositol-3-kinase Delta Inhibitors via a Common Intermediate Approach

This paper describes the discovery and development of a flexible route to two candidate drug molecules by a common intermediate approach. Key reactions include Negishi and Suzuki couplings to form biaryl bonds. Conditions for a Miyaura borylation of heteroaryl bromides were also developed. Heteroaryl trifluoroborates and aryl chlorides were used as coupling partners in the Suzuki reaction, thereby minimizing detrimental side reactions such as protodeboronation and oxidative homocoupling. A complementary set of reaction conditions using pinacolboronates with potassium bifluoride as an additive were also developed and used to make 5 kg of drug substance for use in early-phase clinical trials.